Navigation Links
A vaccine to kill tapeworm

A Vaccine for pigs could help save the 50,000 people a year in poor countries killed by a gruesome parasite. Initial trials suggest it is nearly 100 per cent effective.

The vaccine, developed by a team at the University of Melbourne, Australia, targets a tapeworm called Taenia solium. The adult form, caught from eating undercooked pork, grows only inside the human intestine, stealing nutrients from the host.

This can be debilitating. But far worse is what can happen if people swallow any of the microscopic eggs shed in vast numbers in the faeces of those carrying the adult form. The eggs hatch in the intestine and the immature parasites, known as oncospheres, burrow through the gut wall. They then migrate through the body and lodge themselves in muscles, the eyes and the brain, causing a disease called cysticercosis.

Its symptoms vary depending on the location and number of what are called cysticerci. Many people have no serious symptoms, but some go blind, become confused, suffer difficulty with balance or have epileptic seizures. Heavy infections can kill, often as a result of inflammation after the parasites die. The parasite has been virtually eliminated in developed countries, but even in the US there are around 1000 cases each year, mainly among immigrants. In central and South America, Asia and Africa, millions of people have symptoms of the disease.

While humans are the main host for T. solium, pigs are the intermediate host, and an essential step in the tapeworm's life cycle. If a pig eats the eggs then, as in humans, the eggs hatch in the intestine, burrow through the gut wall and travel to muscles, where they form cysticerci. The infection rarely causes symptoms in pigs.

Only cysticerci- not eggs- can develop into the adult form, so if you prevent infection in pigs, you can break the life cycle, says team member Charles Gauci. The Australian group has created a vaccine based on two proteins found on the oncosphere. T he vaccine triggers the production of antibodies by the immune system that cause oncospheres to burst.

Small-scale trials, in which eggs isolated from adult tapeworms were fed to up to 30 pigs, have already been conducted in Mexico, Peru, Cameroon and Honduras. The vaccine provided between 99.5 and 100 per cent protection in every trial. The Melbourne researchers, together with collaborators in Lima, Peru, now have plans for larger field trials in which the pigs will be allowed to forage as normal, they reported at a conference on parasitology in Melbourne last week. At the moment, two vaccinations about one month apart provide several months of immunity. The team's aim is to provide lifelong immunity with one or two shots, though they say the vaccine will still be beneficial even it has to be given yearly.

There is no reason why the vaccine would not work in people too. But safety issues make it much more costly to develop a human vaccine, and it should not be necessary, says Gauci. "An effective control programme would involve treating people with existing drugs to remove tapeworm from a population and preventing the reinfection of the human population by vaccinating pigs," he says.


'"/>

Source:New Scientist Boston office


Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. Norovirus, AIDS vaccine and Hepatitis Virus
7. HIV vaccine trial breaks ground for future research
8. Live vaccines more effective against horse herpes virus
9. NIAID begins clinical trial of West Nile virus vaccine
10. Designing vaccines by computer
11. Wake Forest scientists find new combination vaccine effective against plague
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
Breaking Biology News(10 mins):
(Date:6/15/2017)... ... 15, 2017 , ... Cybrexa Therapeutics, a start-up cancer therapeutics ... in the amount of $6 million. An investment vehicle affiliated with HighCape Partners, ... The Series B funding will enable Cybrexa to complete the build-out of its ...
(Date:6/15/2017)... ... 15, 2017 , ... DuPont Industrial Biosciences (DuPont) announced that ... Bloomberg’s 2017 Sustainable Business Summit: Seattle this Thursday, June 15, at ... a panel titled “Developing a Corporate Renewables Strategy.” , “Consumers want to ...
(Date:6/14/2017)... ... June 14, 2017 , ... The Thailand Board of ... that they’re co-hosting a delegation from Thailand at BIO 2017 in San Diego, ... gathering in the world, regroups more than 1,100 biotech companies, academic institutions, state ...
(Date:6/14/2017)... CA (PRWEB) , ... June 14, 2017 , ... ... cancer diagnostics and personalized medicine technology, today announced four new distribution agreements for ... over the cancer care cycle. The commercial agreements will make ClearID available immediately ...
Breaking Biology Technology: